Results 201 to 210 of about 7,548 (263)

A Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus

Novo Nordisk
openalex   +1 more source

The Effect of Insulin Degludec Versus Insulin Glargine U100 on Glucose Metrics Recorded During Continuous Glucose Monitoring in People With Type 1 Diabetes and Recurrent Nocturnal Severe Hypoglycemia. [PDF]

J Diabetes Sci Technol
Brøsen JMB, Agesen RM, Alibegovic AC, Andersen HU, Beck-Nielsen H, Gustenhoff P, Hansen TK, Hedetoft C, Jensen TJ, Juhl CB, Stolberg CR, Lerche SS, Nørgaard K, Parving HH, Tarnow L, Thorsteinsson B, Pedersen-Bjergaard U.   +16 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Degludec: A Novel Basal Insulin

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2012
Limitations of conventional human basal insulins like NPH have led to the development of more stable and peak less analogs. However, the first generation of basal analogs like glargine and detemir has certain shortcomings which do not allow them to be termed ideal basal insulin. Degludec, a novel basal insulin analog has the potential to overcome these
Sanjay, Kalra, Manash P, Baruah, Asfandyar K, Niazi   +2 more
openaire   +3 more sources

Insulin Degludec: A Novel Basal Insulin Analogue

Annals of Pharmacotherapy, 2013
OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical trial data, adverse effects, and potential role in therapy of insulin degludec. DATA SOURCES: Articles were identified using the MEDLINE database (January 1996-December 2012). Abstracts and posters were identified from respective congressional websites and published supplements of the ...
Jennifer D, Goldman-Levine, Dhiren K, Patel, David M, Schnee   +2 more
openaire   +2 more sources

Insulin degludec – a new-generation basal insulin

Expert Opinion on Biological Therapy, 2012
Insulin degludec may provide dosing options for patients who, because of their lifestyle, require some flexibility in adhering to an insulin regimen, and it may also reduce the risk of hypoglycemia compared with the basal insulins that are currently available.
Ammar, Wakil, Stephen L, Atkin
openaire   +2 more sources

▼Insulin degludec for diabetes mellitus

Drug and Therapeutics Bulletin, 2013
Over the last few years there has been a steady increase in the number of prescriptions dispensed in primary care for intermediate and long-acting insulin analogues and a reduction in prescriptions for biphasic isophane insulin. For example, in England, the volume of intermediate and long-acting insulin analogues in general practice has risen from ...
openaire   +2 more sources

Insulin Degludec

RCSB Protein Data Bank, 2018
Shriya Patel, Shuchismita Dutta
openaire   +2 more sources